Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Bexarotene Gel

Bexarotene Gel EDITORIAL A Food and Drug Administration–Approved Skin-Directed Therapy for Early-Stage Cutaneous T-Cell Lymphoma YCOSIS FUNGOIDES (MF) is the most 67 patients diagnosed as having stages IA through IIA common primary cutaneous T-cell MF (and 1 protocol deviation of stage IIB) who had up lymphoma (CTCL). It is character- to 50% body surface area involvement (mean, 11.7%). ized by malignant T cells that infil- The results of the study showed that bexarotene gel was M trate the skin or extracutaneous sites. well tolerated and efficacious. The most frequent ad- Early-stage MF (limited, generalized patch, and plaque, verse effects were local irritation and erythema, which T1 and T2, stages IA-IIA) is typically limited to the skin. correlated with increases in concentration and fre- Subsequently, the management of early-stage MF fre- quency of application. Most patients tolerated the gel with quently involves skin-directed therapies, which include brief periods of discontinuation, and 35 patients (52%) topical glucocorticoids, nitrogen mustard (mechloretha- applied the gel for longer than a year. Serum sample mea- mine hydrochloride), carmustine, UV-B radiation, pso- surements to assess systemic absorption did not reveal ralen–UV-A radiation, and electron-beam radiation clinically significant levels. Sixty-three percent of pa- therapy. Aggressive therapy with combination chemo- http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Dermatology American Medical Association

Bexarotene Gel

Liu, Howard L.; Kim, Youn H.
JAMA Dermatology , Volume 138 (3) – Mar 1, 2002
Download PDF
2 pages

Loading next page...
 
/lp/american-medical-association/bexarotene-gel-dKFEFNCl5a

References (6)

Publisher
American Medical Association
Copyright
Copyright 2002 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6068
eISSN
2168-6084
DOI
10.1001/archderm.138.3.398
Publisher site
See Article on Publisher Site

Abstract

EDITORIAL A Food and Drug Administration–Approved Skin-Directed Therapy for Early-Stage Cutaneous T-Cell Lymphoma YCOSIS FUNGOIDES (MF) is the most 67 patients diagnosed as having stages IA through IIA common primary cutaneous T-cell MF (and 1 protocol deviation of stage IIB) who had up lymphoma (CTCL). It is character- to 50% body surface area involvement (mean, 11.7%). ized by malignant T cells that infil- The results of the study showed that bexarotene gel was M trate the skin or extracutaneous sites. well tolerated and efficacious. The most frequent ad- Early-stage MF (limited, generalized patch, and plaque, verse effects were local irritation and erythema, which T1 and T2, stages IA-IIA) is typically limited to the skin. correlated with increases in concentration and fre- Subsequently, the management of early-stage MF fre- quency of application. Most patients tolerated the gel with quently involves skin-directed therapies, which include brief periods of discontinuation, and 35 patients (52%) topical glucocorticoids, nitrogen mustard (mechloretha- applied the gel for longer than a year. Serum sample mea- mine hydrochloride), carmustine, UV-B radiation, pso- surements to assess systemic absorption did not reveal ralen–UV-A radiation, and electron-beam radiation clinically significant levels. Sixty-three percent of pa- therapy. Aggressive therapy with combination chemo-

Journal

JAMA Dermatology – American Medical Association

Published: Mar 1, 2002

There are no references for this article.